Mortality results in GUSTO.
The mortality results for the four arms of the GUSTO trial are presented. The 30 day mortality results were as follows: streptokinase (SK) and subcutaneous heparin (n = 9796), 7.2%, SK and intravenous heparin (n = 10,377) 7.4%, accelerated tissue plasminogen activator (t-PA) and intravenous heparin (n = 10,344) 6.3%, and combined SK and t-PA (n = 10,328) 7.9%. This is a relative risk reduction of 14% for the accelerated t-PA regimen compared with the two SK regimens equivalent to an absolute risk reduction of ten lives saved per 1000 patients treated. Predefined subgroups who showed a greater benefit with t-PA versus SK were patients under the age of 75, anterior infarct location and those treated within four hours of onset of symptoms.
Van de Werf
F
F
Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.
D000368:Aged; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality*; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000627:therapeutic use; D015996:Survival Rate; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator